Table A1.
Compound | Model | Protein Expression | Glucose Uptake (GU)/ Blood Glucose (BG)/ Insulin Sensitivity (IS) |
Additional Findings | Treatment | Reference |
---|---|---|---|---|---|---|
Chlorogenic acid |
L6 myotubes | GLUT4 | GU | ↑ PPARγ protein | 25 μM for 5 h: cytotoxicity > (50 μM) | [63] |
Cinnamon and extracts |
C2C12 myotubes | p-AMPK | GU | 100 or 1000 μg/mL for 3 h | [64] | |
C2C12 myotubes | 30 μg/mL for 4 h | [65] | ||||
Wistar rats (WR) (gastrocnemius muscle) |
GLUT4 | ↑ NEFA (serum), ↓ serum creatine ↑ GLUT4 |
30 mg/kg/day for 22 days | [66] | ||
C57BL/6J mice | BG | ↓ NEFA (serum), ↓ LDL-C, ↓ insulin |
Overnight fast. 400 mg/kg/day for 21 days |
[67] | ||
db/db mice | BG | ↓ NEFA (serum) ↓ fasting blood glucose level |
6 h fast. 400 mg/kg/day for 14 days |
|||
C57BL/6J mice | BG | ↑ IRS-1, IR protein | Overnight fast. 150 mg/kg/day for 14 days |
[68] | ||
C57BLKS/J db/db mice | BG | ↑ HDL-C levels (serum) ↓ p-Akt, Upregulated mRNA GLUT4 ↑ p-Akt |
20 mg/kg/day (p.o.) for 4 weeks | [69] | ||
Curcumin | C2C12 myotubes | p-Akt, p-AMPK | ↑ p-ACC protein ↑ GU ↑ GLUT4 translocation ↑ p-AMPK ↑ p-ACC ↑ p-Akt (insulin-induced) |
40 μM for 24 h: cytotoxicity > 40 μM 40 µM for 1 h |
[70] | |
WR (soleus muscle) | p-AMPK | BG | 1 μM for 30 min or 60 mg/kg | [71] | ||
C2C12 cells | ↑ GU ↓ p-IRS-1 ↓ p-ACC ↑ p-Akt ↑ p-ERK1/2 ↑ p-p38 MAPK |
20 µM for 2 h | [72] | |||
C2 murine myoblasts | ↑ Apoptosis ↓ Cell viability ↑ PARP fragmentation ↑ p-JNK |
50 µM for 24 h | [73] | |||
L6myc skeletal muscle cells | ↑ GLUT4 translocation ↑ p-Akt ↑ p-GSK-3β ↓ TNF-α, IL-6 and MCP-1 levels ↑ IL-10 levels |
25 µM for 16 h | [74] | |||
ECGC | L6 myotubes | p-Akt, p-AMPK | GU | 40 μM for 3 h | [75] | |
SD rats (soleus muscle) |
12 h fast. 75 mg/kg for 1 h, or 100 nM for 15 min |
[29] | ||||
C57BL/6 mice (soleus muscle) |
12 h fast. 75 mg/kg for 1 h, or 100 nM for 15 min |
|||||
L6 myotubes | GU | 100 nM for 15 min | ||||
C2C12 myotubes | p-Akt, p-AMPK | ↑ p-p38 MAPK, ↑ p-ACC |
20 μM up to 72 h: treatment not cytotoxic up to 48 h |
[72] | ||
L6 myotube | GLUT4 | ↑ PI3K, ↓ PKC λ/ξ ↑ GLUT4 RNA, ↑ Rac1 |
1 nM | [76] | ||
ICR mice | GLUT4, PI3K, p-AMPK | ↑ GLUT4, glycogen accumulation in skeletal muscle |
Oral administration postprandial hyperglycemia | |||
C2C12 myotubes (ßGlud1−/−) |
p-AMPK | ↑ p-AMPK, ↑ GU, ↑ IS |
20 µM EGCG for 10 min | [77] | ||
Ellagic acid | 3T3-L1 adipocytes and C2C12 myotubes | GLUT4, p-AMPK | GU | ↑ GLUT4 ↑ p-AMPK ↑ p-ERK1/2 ↑ p-PKC ζ/λ |
50 μg/mL for 1 h 1, 10, 100, 500 nM |
[33] |
Ferulic acid | L6 myotubes | GLUT4 | GU | ↑ PI3K protein | 5 μM for 5 h: cytotoxicity > (50 μM) | [63] |
Gingerol | L6 myotubes | GU | 40 μg/mL for 48 h: treatment not cytotoxic | [78] | ||
Naringenin | L6 myotubes | p-AMPK | GU | 150 μM for 2 h | [79] | |
Quercetin | ob/ob mice (gastrocnemius muscle) |
GLUT4 | BG, IS | ↑ GLUT4 RNA, ↓ TNF-α, ↓ iNOS RNA, ↓ NF κB activation |
30 mg/kg alternating days for 10 weeks | [80] |
L6 myotubes | p-Akt | GU | 200 μM for 48 h | |||
Kunming mice (gastrocnemius muscle) |
GLUT4, p-AMPK | BG | ↑ p-ACC, ↓ blood triacylglycerol, ↓ total cholesterol, |
12-h fast. 5, 10, 20 mg/kg/day for 13 weeks |
[81] | |
C2C12 myotubes | GLUT4, p-AMPK | GU | ↑ PPARα, ACC, MCAD, CPT-1, GLUT4, PGC-1α RNA, p-ACC protein |
10 μM for 24 h: treatment not cytotoxic |
||
C2C12 myotubes | GU | ↑ p-ACC protein | 100 μM for 18 h | [81] | ||
C2C12 myotubes | p-AMPK | GU | enhanced glucose uptake by 38–59% stimulated uptake by 37%, stimulated the AMPK pathway (25–100 mM) inhibited ATP synthase (in mitochondria) by 34 and 79% |
quercetin-3-O-glycosides (50 mM; 18 h treatment) in the absence of insulin quercetin aglycone and quercetin glycosides quercetin aglycone by 25 and 100 mM |
[82] | |
L6 myotubes | CaMKKβ/AMPK, IRS1/PI3K/Akt JAK/STAT |
GU | ↑ GU (0.1 nM and 1 nM quercetin or 1 nM isorhamnetin) ↑ JAK/STAT (1 nM and 10 nM isorhamnetin) ↑ p-AMPK (quercetin) ↑ JAK2/STAT (isorhamnetin) ↑ IRS-1 (at 10 nM) |
[34] | ||
ICR mice | GLUT4 | GU | quercetin aglycone form were 4.95 and 6.80 nM (plasma concentration) | 10, 100 and 1000 mg/kg body weight | ||
Resveratrol | L6 myotubes | p-AMPK | GU | 100 μM for 4 h | [83] | |
db/db mice | BG | ↑ Glucose tolerance | 5 mg/mL/100g body weight for 3 weeks † | |||
SD rats (soleus muscle) |
GU, BR | Overnight fast. 10 mg/kg/day for 16 weeks |
[84] | |||
C2C12 myotubes | GU | 10 μM for 24 h | ||||
L6 myotubes | p-AMPK | GU | 100 μM for 2 h: cell morphology unaltered up to 125 μM |
[85] | ||
SD rats (soleus muscle) |
GU | ↑ p-ERα, ↑ p-IR, ↓ serum cholesterol, ↓ triglycerides, ↓ uric acid |
1 mg/kg/day for 15 days or 15 weeks | [86] | ||
C2C12 myotubes | p-Akt | GU | ↑ p-ERα, ↑ p-p38 MAPK, ↑ p-ERK, ↑ p-IR |
0.1 μM for 14 h: treatment not cytotoxic |
||
WR (soleus muscle) | GLUT4, p-Akt | BG | ↑ PEPCK | Overnight fast. 0.05–10 mg/kg/day for 7 days |
[87] | |
C2C12 myotubes | GU | 30 μM for 30min | ||||
C2C12 myocytes | p-AMPK | ↑ PGC-1α RNA | 50 μM for 24 h: cytotoxicity > (50 μM) | [88] | ||
SIRT1 knockout mice | BG, IS | ↓Mitochondrial content and respiration | 100 mg/kg day for 9 weeks | [89] | ||
Green tea | Wistar rats (WR) | GLUT4 | ↓ Triacylglycerols (plasma) ↓ NEFA, ↓ HbA1c, ↑ GLUT4 |
50 mg/kg body weight for 12 days | [90] | |
KK-Ay mice | GLUT4 | IS | ↓ Triacylglycerols (plasma) | 4 weeks | ||
Procyanidins (dimer to tetramer) from black soybean seeds | ICR mice (soleus muscle) | GLUT4 | GU | ↑ GLUT4 ↑ p-IRS-1 ↑ p-AMPK ↑ plasma insulin level ↑ plasma adiponectin ↓ plasma glucose |
EC and C3G in water at 10 μg/kg body weight | [91] |
Procyanidins from cocoa liquor (CLPr) | L6 myoblasts | GLUT4 | GU | ↑ GLUT4 (7 days) GLUT1 unchanged |
250 mg/mL CLPr in DMSO | [92] |
ICR mice (soleus muscle) | GLUT4 | GU | ↑ GLUT4 (7 days) GLUT1 unchanged |
1, 5, 10 μg/mL single oral administration | ||
High-molecular-weight cocoa procyanidins | human primary skeletal muscle cells | GLUT4, PI3K/AKT, p-AMPK |
GU | ↑ glycogen synthesis (cocoa extract), ↑ glycogen synthase (GS) (monomers 30% at 10 μM, oligomers 62% at 10 μM, polymers 16% at 10 μM and 32% at 25 μM) ↑ GU (all doses) ↓ PI3K/AKT (CE, 25 μM; oligomer, 25 μM; polymer 10 and 25 μM) |
10 and 25 μM | [93] |
Sinapic acid | SZT-diabetic rats (soleus muscle) | GLUT4 | GU | ↑ reduced glucose infusion rate (GIR) | 5 mg/kg, 10 mg/kg, and 25 mg/kg | [94] |
L6 cells | GU | ↓ PLC-PKC signals ↑ glucose uptake |
||||
Gallic acid | 3T3-L1 cells | GLUT4 | GU | ↑ GLUT4 ↑ PKCζ/λ |
1 µM, 10 µM, 20 µM | [95] |
HFD SZT-diabetic rats (adipose tissue) |
GLUT4 | GU | ↑ PPARγ ↑ GLUT4 ↑ PI3K/p-Akt ↑ GU |
20 mg/kg | [96] | |
Black tea polyphenols (theaflavin) | L6 myotubes | GLUT4, p-AMPK | GU | ↑ p-IRS1 ↑ p-AMPK/AMPK ↑ p-GSK-3β ↑ PI3K |
0.1, 1.0, 10 BTP µg/mL | [32] |
Rosemary extract | L6 myotubes | p-AMPK, GLUT4 | GU | ↑ GU (5 µg/mL) ↑ p-AMPK ↑ p-ACC protein ↑ p-PKC |
5 µM RA for 4 h (maximum) | [97] |
Carnosol | L6 myotubes GLUT4myc |
p-AMPK, GLUT4, p-Akt |
GU | ↑ p-Akt ↑ p-mTOR ↑ p-ACC protein ↑ GLUT4 |
25 µM carnosol (4 h) | [31] |